GlassScriptPhysician profile
Sumyra Kachru
NPI 1093003394
$3,456.12
in general payments reported to CMS, 2019-2025
21 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.06 · 2021: $278 · 2022: $565 · 2023: $1,029 · 2024: $993 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $767.58 | 2021-2025 | |
| Qol Medical, LLC | $354.24 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $337.12 | 2021-2025 | Stelara, Remicade, Simponi Aria |
| Celgene Corporation | $305.67 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $219.09 | 2022-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $166.71 | 2023 | Rebyota |
| Lucid Diagnostics INC. | $140.37 | 2025 | |
| Mallinckrodt Hospital Products INC. | $136.49 | 2022-2024 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $125.99 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.03 | 2022-2025 | Trulance, Xifaxan |
| Genzyme Corporation | $122.73 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $109.64 | 2024-2025 | Voquezna |
| Pentax of America, INC. | $99.21 | 2024 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Olympus America INC. | $98.86 | 2023 | Evis Exera III Gastrointestinal Videoscope |
| Boston Scientific Corporation | $98.06 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $68.06 | 2022-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $62.13 | 2024 | Resmetirom |
| Enterra Medical, INC. | $51.69 | 2025 | |
| Daiichi Sankyo INC. | $24.61 | 2022 | |
| Coloplast Corp | $23.77 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumyra Kachru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.